This article summarized the latest R&D progress of Retapamulin, the mechanism of action for Retapamulin, and the drug target R&D trends for Retapamulin.

On 23 Oct 2023, the phase Ib/II clinical trial result of Cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma was reported at the ESMO Congress.

Monte Rosa Therapeutics unveils preclinical findings. The research indicates that MRT-6160, a VAV1-specific molecular glue breaker, may be effective in treating immune-based and inflammatory disorders.

Calcineurin inhibitors, acting as immunosuppressive agents, are employed in the treatment of autoimmune disorders like lupus nephritis, atopic dermatitis, interstitial lung disease, and idiopathic inflammatory myositis, among others.

This article summarized the latest R&D progress of Reteplase, the Mechanism of Action for Reteplase, and the drug target R&D trends for Reteplase.

Sunvozertinib (DZD9008) is a targeted, irreversible EGFR inhibitor selective for EGFR mutations. Initial findings for sunvozertinib in treating naïve EGFR exon20ins NSCLC were presented at the ESMO Congress.

At SITC 2023, ENB Therapeutics showcased preliminary findings from the first phase of its ENBOLDEN-101 trial for platinum-resistant ovarian cancer.

C5 inhibitors can defend against biological attacks and control diseases caused by immune responses.

This article summarized the latest R&D progress of Rimegepant Sulfate, the mechanism of action for Rimegepant Sulfate, and the drug target R&D trends for Rimegepant Sulfate.

On October 20, 2023, a novel extended-release siRNA targeting KRASG12D/V (G12D/V) mutations (Loder) in combination with standard chemotherapy was reported at the ESMO Congress.

Qualigen Therapeutics reports the initial dosage in the Phase 1a QN-302 Clinical Study for Advanced or Metastatic Solid Tumors has been administered to the first patient.

Bruton's Tyrosine Kinase (BTK) inhibitors present a promising treatment for B-cell malignancies. Over the past decade, numerous clinical trials involving BTK inhibitors with anticancer potential have commenced, signaling a bright future for BTK inhibitors.